REG - IXICO plc - Result of GM and Update on Issue of Equity

IXICOAnnouncement

Yesterday 12:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260416:nRSP7973Aa&default-theme=true

RNS Number : 7973A  IXICO plc  16 April 2026

16 April 2026

 

 IXICO PLC

("IXICO" or the "Company")

Result of General Meeting and Update on Issue of Equity

IXICO plc (AIM: IXI), a global leader in neuroscience imaging and biomarker
analytics, using its AI-driven platform to help advance drug development in
neurological disorders, announces that all resolutions put to Shareholders at
the General Meeting held earlier today in connection with the Placings,
Subscription and Retail Offer, as announced by the Company on 31 March 2026,
were duly passed.

    Resolution                                                                       For                      Against                  Total                   Withheld
                                                                                     Number of votes  %       Number of votes  %       Number of votes  %      Number of votes
 1  To authorise the Directors to allot relevant securities for cash up to an        47,575,433       78.67%  12,895,688       21.33%  60,471,121       65.26  10,829
    aggregate nominal amount of £1,312,500 in connection with the Fundraising and
    a further £746,395 pursuant to an ongoing general authority
 2  To authorise the Directors of the Group to adopt the Non-Employee Sub-Plan to    46,575,493       77.02%  13,900,162       22.98%  60,475,655       65.26  6,295
    the IXICO Share Option Plan
 3  To authorise the Directors to issue and allot equity securities on a             47,550,738       78.63%  12,924,915       21.37%  60,475,653       65.26  6,297
    non-pre-emptive basis up to a maximum aggregate nominal amount of £1,312,500
    for cash on a non-pre-emptive basis in connection with the Fundraising and a
    further £223,918 pursuant to an ongoing general authority

 

·      A vote Withheld is not a vote in law and is not counted in the
calculation of the votes cast For or Against the resolution, nor in the
calculation of the percentage of issued share capital voted for any
resolution.

·      Votes For and Against are expressed as a percentage of votes
validly cast for that resolution by proxy, excluding any Withheld votes.

Update on Issue of Equity and Advanced Assurance

As announced in the 'Placings and Subscription' RNS dated 31 March 2026, the
First Placing and Subscription are conditional, amongst other things, on (a)
the passing of certain shareholder resolutions at a General Meeting; and (b)
receipt of Advanced Assurance from HM Revenue & Customs issued under the
Income Tax Act 2007; and (c) admission of the New Ordinary Shares to trading
on AIM, initially expected to be 17 April 2026 in respect of First Admission
and 20 April 2026 in respect of Second Admission. As of the date of this
announcement, the Company has not yet received Advance Assurance from HM
Revenue & Customs but expects to do so shortly. The Company will make a
further announcement in due course to advise the market of the revised
timetable for both the First Admission and the Second Admission, together with
confirmation of the Company's total voting rights. The Company notes that the
First Admission Long Stop Date is 17 May 2026 and the Second Admission Long
Stop Date is 19 May 2026.

Capitalised terms used in this announcement have the meaning given to them in
the announcement dated 31 March 2026, unless otherwise defined in this
announcement.

 

 

Enquiries:

 IXICO plc                                                          +44 (0) 20 3763 7499
  Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited (Nominated advisor and broker)   +44 (0) 20 7220 0500
 Giles Balleny, Isaac Hooper, Andrea Callaghan (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

Michael F Johnson (Sales)

 

 About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMUNRARNRUSAAR



            Copyright 2019 Regulatory News Service, all rights reserved